COVID-19 Vaccine Protects Leaky Gut Sufferers

,� said study author Abhishek Bhurwal, an Advanced IBD Fellow in the Division of Gastroenterology and Hepatology at the Rutgers Robert Wood Johnson Medical School.

An estimated 3.1 million adults in the United States have been diagnosed with IBD, according to the Centers for Disease Control and Prevention. The disease, which includes Crohn???? disease and ulcerative colitis, causes chronic inflammation of the gastrointestinal tract.


The systematic analysis focused on four key aspects of COVID-19 vaccination of IBD patients: the strength of their immune response to the vaccine; the occurrence of breakthrough infections after taking the vaccine; the occurrence of adverse events to the vaccine; and whether differing IBD treatments affected vaccine effectiveness.

They found that vaccinated IBD patients showed high levels of antibody response, known as seroconversion, two weeks after the first vaccine, indicating a strong, positive response to the vaccine.

Vaccinated IBD patients did not experience a higher or lower rate of breakthrough infections than the control group in studies. They also experienced a low rate of adverse events, and the most common events have also been seen in the general population: reactions at the injection site; headaches; backache; and joint pain.

Because of their treatment with immunosuppressive drugs, IBD patients are more susceptible to infectious diseases than the general population. As a result, they have been encouraged to receive COVID-19 vaccines.

Vaccinated IBD patients with different immunosuppressive treatments had a similar response to the vaccine. Further studies are needed for assessing patients on corticosteroids for IBD.

However, the studies analyzed were likely not designed to allow for more subtle distinctions. Additionally, further studies regarding the effectiveness of variants and booster doses are needed.

Source: Medindia

Stay connected with us on social media platform for instant update click here to join our  Twitter, & Facebook

We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

For all the latest Health News Click Here 

 For the latest news and updates, follow us on Google News

Read original article here

Denial of responsibility! TechiLive.in is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.